← FDA DRUG APPROVALS

FDA ANDA · ANDA040800

OXYCODONE AND ACETAMINOPHEN

Sponsor: ACTAVIS ELIZABETH

APPLICATION
ANDA040800
TYPE
ANDA
ORIGINAL APPROVAL
2012-04-03
LATEST ACTION
2026-06-18
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

OXYCODONE AND ACETAMINOPHENDiscontinued
ACETAMINOPHEN 325MG, OXYCODONE HYDROCHLORIDE 7.5MG · TABLET · ORAL
OXYCODONE AND ACETAMINOPHENDiscontinued
ACETAMINOPHEN 325MG, OXYCODONE HYDROCHLORIDE 10MG · TABLET · ORAL

Approval history

2026-06-18REMS · Supplement 16AP
2025-12-22Labeling · Supplement 15 · standardAP
2024-10-31REMS · Supplement 14AP
2024-03-12Labeling · Supplement 13 · standardAP
2024-03-12Labeling · Supplement 12 · standardAP
2023-12-15Labeling · Supplement 11 · standardAP
2023-12-15Labeling · Supplement 10 · standardAP
2021-03-04Labeling · Supplement 9 · standardAP
2019-10-08Labeling · Supplement 7 · standardAP
2018-09-21Labeling · Supplement 6 · standardAP
2018-09-18REMS · Supplement 5AP
2016-12-16Labeling · Supplement 4 · standardAP
2016-12-16Labeling · Supplement 3 · standardAP
2016-03-28Labeling · Supplement 1 · standardAP
2012-04-03OriginalREMSAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →